Scientists have discovered that the peptide hormone adrenomedullin plays a pivotal role in obesity-related type 2 diabetes, ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...

Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study.

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...